Evaluation of the Dynamics of Serum Levels of Matrix Metalloproteinases in the Acute Period of Ischemic Stroke

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Objective — evaluation of serum levels of MMP- 2 and MMP- 9 in patients during the acute period of ischemic stroke in the context of clinical and functional recovery. The study included 114 patients with ischemic stroke. Patient groups: Group 1 — mild stroke (n = 57 patients), Group 2 — moderate stroke (n = 25 patients), Group 3 — severe stroke (n = 32 patients). Observation period: 14 days. Observation points: I — the first 48–72 hours from the onset of the disease; II — the 14th day. Assessment scales: National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS). MMP- 2 and MMP- 9 were determined in blood serum using the ELISA method. Statistical processing of the results was carried out using the Statistica 13.0. Patients of groups 1 and 2 showed a statistically significant decrease of points on the NIHSS and mRs scales (p<0.001) in the dynamics of observation, patients of group 3 no significant changes were found (p = 0.157 and p = 0.315, respectively). MMP- 2 and MMP- 9 in the blood of the comparison group did not differ significantly relative to patients at two observation points. A reliable difference in MMP- 2 was revealed in all groups with a tendency to decrease between patients of groups 1 and 3 (p1-3 = 0.03 and p1-3 = 0.014, respectively). Comparative analysis of MMP- 2 showed a decrease in the marker in the dynamics of the acute period of group 3 (p1-II = 0.043). A negative correlation was found in patients of group 2 between mRs_ I and MMP- 2_ II (r = - 0.611; p = 0.027). Intergroup analysis of MMP- 9 and analysis of the dynamics of marker changes by the end of the observation period did not show significant differences. Δ MMP- 9 = 75 [−38, 302] ng/ml in group 1 and positively correlated with mRs_ II (r = 0.613; p = 0.034). MMP- 2 and MMP- 9 in patients' serum are promising as prognostic biomarkers of ischemic stroke, but their temporal variability and multifunctionality make their clinical application difficult.

About the authors

K. S. Kucherova

Siberian State Medical University

Email: kristyajka@ya.ru
Tomsk, Russia

E. S. Koroleva

Siberian State Medical University

Tomsk, Russia

V. M. Alifirova

Siberian State Medical University

Tomsk, Russia

N. G. Brazovskaya

Siberian State Medical University

Tomsk, Russia

L. A. Levchuk

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

Tomsk, Russia

S. A. Ivanova

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

Tomsk, Russia

References

  1. Jayaraj R.L., Azimullah S., Beiram R., Jalal F.Y., Rosenberg G.A. // J Neuroinflammation. 2019. V. 16. P. 142.
  2. Candelario-Jalil E., Djikhuizen R.M., Magnus T. // Stroke. 2022. V. 53. P. 1473–1486.
  3. Qin C., Yang S., Chu Y.H., Zhang H., Pang X.W., Chen L., Zhou L.Q., Chen M., Tian D.S., Wang W. // Signal Transduct. Target. Ther. 2022. V. 7. P. 215.
  4. Ji Y., Gao Q., Ma Y., Wang F., Tan X., Song D., Hoo R.L.C., Wang Z., Ge X., Han H., Guo F., Chang J. // Pharmacol. Res. 2023. V. 190. P. 106720.
  5. Montaner J., Ramiro L., Simats A., Hernández–Guillamon M., Delgado P., Bustamante A., Rosell A. // Cell. Mol. Life Sci. 2019. V. 76. P. 3117–3140.
  6. Planas A.M., Solé S., Justicia C. // Neurobiol. Dis. 2001. V. 8. P. 834–846.
  7. Zhao B.Q., Wang S., Kim H.Y., Storrie H., Rosen B.R., Mooney D.J., Wang X., Lo E.H. // Nat. Med. 2006. V. 12. P. 441–445.
  8. Maestrini I., Ducroquet A., Moulin S., Leys D., Cordonnier C., Bordet R. // Rev. Neurol. (Paris). 2016. V. 172. P. 198–219.
  9. Lakhan S.E., Kirchgessner A., Tepper D., Leonard A. // Front. Neurol. 2013. V. 4. P. 1–15.
  10. Turner R.J., Sharp F.R. // Front. Cell. Neurosci. 2016. V. 10. P. 1–13.
  11. Goldstein L.B., Samsa G.P. // Stroke. 1997. V. 28. P. 307–310.
  12. Adams H.P. Jr., Bendixen B.H., Kappelle L.J., Biller J., Love B.B., Gordon D.L., Marsh E.E. // Stroke. 1993. V. 24. P. 35–41.
  13. Sun J. // J. Signal. Transduct. 2010. V. 2010. P. 985132.
  14. Wang D., Saleem S., Sullivan R.D., Zhao T., Reed G.L. // Int. J. Mol. Sci. 2024. V. 25. P. 9442.
  15. Sood R.R., Taheri S., Candelario—Jalil E., Estrada E.Y., Rosenberg G.A. // J. Cereb. Blood Flow Metab. 2008. V. 28. P. 431–438.
  16. Kreisel S.H., Stroick M., Reuter B., Senn E., Hennerici M.G., Fatar M. // J. Clin. Neurosci. 2012. V. 19. P. 1564–1567.
  17. Lucivero V., Prontera M., Mezzapesa D.M., Petruzzellis M., Sancilio M., Tinelli A., Di Noia D., Ruggieri M., Federico F. // Neurol. Sci. 2007. V. 28. P. 165–170.
  18. Shi Y. // Lancet Neurol. 2021. V. 18. P. 1058–1066.
  19. Montaner J., Alvarez-Sabin J., Molina C., Anglés A., Abilleira S., Arenillas J., González M.A., Monasterio J. // Stroke. 2001. V. 32. P. 1759–1766.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Russian Academy of Sciences

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).